A COMPARISON BETWEEN TREATMENT RESPONSE OF CHRONIC MYELOID LEUKEMIA PATIENTS RECEVING IMATINIB OR NILOTINIB

This study aimed to evaluate early hematologic responses after three months of TKI therapy in CML patients and to assess the influence of demographic and clinical factors on treatment outcomes.

本研究旨在评估慢性髓系白血病（Chronic Myeloid Leukemia, CML）患者接受酪氨酸激酶抑制剂（Tyrosine Kinase Inhibitor, TKI）治疗三个月后的早期血液学应答，并分析人口统计学与临床因素对治疗结局的影响。